Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessing Medicaid Coverage for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy: A Project from the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program ACCESS Initiative.
Auletta JJ, Khera N, DeMartino P, Kelkar AH, Yusuf RA, Davies SM, Knutson J, Beaver E, Maloney A, Majhail NS. Auletta JJ, et al. Among authors: kelkar ah. Transplant Cell Ther. 2023 Nov;29(11):713-720. doi: 10.1016/j.jtct.2023.08.007. Epub 2023 Aug 12. Transplant Cell Ther. 2023. PMID: 37579920
Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Vergara-Cadavid J, Johnson PC, Kim HT, Yi A, Sise ME, Leaf DE, Hanna PE, Ho VT, Cutler CS, Antin JH, Gooptu M, Kelkar AH, Wells SL, Nikiforow S, Koreth J, Romee R, Soiffer RJ, Shapiro RM, Gupta S. Vergara-Cadavid J, et al. Among authors: kelkar ah. Transplant Cell Ther. 2023 Jul;29(7):455.e1-455.e9. doi: 10.1016/j.jtct.2023.03.029. Epub 2023 Apr 2. Transplant Cell Ther. 2023. PMID: 37015320
Family Caregiver Experiences in the Inpatient and Outpatient Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Settings: A Qualitative Study.
Gray TF, Do KM, Amonoo HL, Sullivan L, Kelkar AH, Pirl WF, Hammer MJ, Tulsky JA, El-Jawahri A, Cutler CS, Partridge AH. Gray TF, et al. Among authors: kelkar ah. Transplant Cell Ther. 2024 Jun;30(6):610.e1-610.e16. doi: 10.1016/j.jtct.2023.09.023. Epub 2023 Sep 30. Transplant Cell Ther. 2024. PMID: 37783339
Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival.
Shapiro RM, Kim HT, Dulery R, Liney D, Garrity HM, Panaro KM, Au C, Gervais C, Little JS, Ho VT, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar AH, Romee R, Wu CJ, Ritz J, Soiffer RJ, Nikiforow S. Shapiro RM, et al. Among authors: kelkar ah. Blood Adv. 2024 May 15:bloodadvances.2023012418. doi: 10.1182/bloodadvances.2023012418. Online ahead of print. Blood Adv. 2024. PMID: 38748871
Trends in Volumes and Survival After Hematopoietic Cell Transplantation in Racial/Ethnic Minorities.
Khera N, Ailawadhi S, Brazauskas R, Patel J, Jacobs B, Ustun C, Ballen K, Abid MB, Díaz MA, Al-Homsi AS, Hashem H, Hong S, Munker R, Schears R, Lazarus HM, Ciurea SO, Badawy SM, Savani BN, Wirk B, LeMaistre CF, Bhatt NS, Beitinjaneh A, Aljurf M, Sharma A, Cerny J, Knight JM, Kelkar AH, Yared JA, Kindwall-Keller T, Winestone LE, Steinberg A, Arnold SD, Seo S, Preussler JM, Hossain NM, Fingrut WB, Agrawal V, Hashmi S, Lehmann LE, Wood WA, Rangarajan HG, Saber W, Hahn T. Khera N, et al. Among authors: kelkar ah. Blood Adv. 2024 Apr 25:bloodadvances.2023012469. doi: 10.1182/bloodadvances.2023012469. Online ahead of print. Blood Adv. 2024. PMID: 38661372
Vaccination of Adults With Cancer: ASCO Guideline.
Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, Kelkar AH, Law LY, LeFebvre KB, Ljungman P, Miller ED, Meyer LA, Moore HN, Soares HP, Taplitz RA, Woldetsadik ES, Kohn EC. Kamboj M, et al. Among authors: kelkar ah. J Clin Oncol. 2024 May 10;42(14):1699-1721. doi: 10.1200/JCO.24.00032. Epub 2024 Mar 18. J Clin Oncol. 2024. PMID: 38498792
51 results